Mizuho initiated coverage on Relmada Therapeutics with a new price target
$RLMD
Biotechnology: Pharmaceutical Preparations
Health Care
Mizuho initiated coverage of Relmada Therapeutics with a rating of Buy and set a new price target of $50.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/5/2024 | $23.00 → $1.00 | Outperform → Neutral | Mizuho |
| 9/17/2024 | $3.50 → $13.00 | Hold → Buy | Jefferies |
| 6/5/2024 | $3.00 → $2.00 | Neutral → Sell | Goldman |
| 10/14/2022 | $81.00 → $8.00 | Buy → Neutral | Goldman |
| 10/14/2022 | $90.00 → $10.00 | Buy → Hold | Truist |
| 10/14/2022 | Buy → Neutral | Guggenheim | |
| 10/13/2022 | $64.00 → $7.00 | Outperform → Perform | Oppenheimer |
| 12/20/2021 | $50.00 → $42.00 | Outperform | SVB Leerink |
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13753596Webcast Access: Click Here A replay of the webcast will be available in the
Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome Cash balance of $44.8 million as of December 31 2024 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today provided a corporate update and announced preliminary and unaudited financial re
CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Information: Date: Thursday, March 27, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13751458Webcast Access: Click Here A replay of the webcast will be av
Mizuho downgraded Relmada Therapeutics from Outperform to Neutral and set a new price target of $1.00 from $23.00 previously
Jefferies upgraded Relmada Therapeutics from Hold to Buy and set a new price target of $13.00 from $3.50 previously
Goldman downgraded Relmada Therapeutics from Neutral to Sell and set a new price target of $2.00 from $3.00 previously
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13753596Webcast Access: Click Here A replay of the webcast will be available in the
90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release "GEM/DOCE" formulation* NDV-01 showed promising clinical activity in BCG-naïve and BCG-unresponsive patients, with favorable overall tolerability Data to be reviewed at Investor Event on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced that positive initial data from the Phase 2 study of NDV-01 showed that 90% of patients achieved high-grade disease-free status at any time point
CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas. Abstract OverviewAbstract Title: Prospective Open Label Study to Evaluate the Safety and Efficacy of intravesical sustained release Gemcitabine Docetaxel combination (NDV-01) in High Risk NMIBCSession: Clinical Trials in Progress: Bladder CancerLocation: Hall C, The Square, Learning LabPresentation Date: April 28, 2025Presentation Time 10:04 AM PT to 10:12 AM PT About NDV-01NDV-01 is an
CORAL GABLES, Fla., Jan. 12, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Fabiana Fedeli, Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of the United Kingdom's largest and longest established investment houses, as an independent director to the Company's Board of Directors. Ms. Fedeli has extensive knowledge of international capital markets, sustainability, governance and corporate strategy
CORAL GABLES, Fla., Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer. Dr. O'Gorman will lead medical, clinical and regulatory functions in support of the Company's late-stage REL-1017 development program. Dr. O'Gorman brings to Relmada more than two decades of life sciences experience in clinical development, medical affairs and medical strategy, with significant expertise
Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022 CORAL GABLES, Fla., July 21, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of John Hixon to a newly created position as Head of Commercial. Mr. Hixon has over 36 years of commercial planning and marketing experience within the biopharmaceutical industry. "My due diligence performed before joi
424B5 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)